MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.

This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Tenosynovial Giant Cell Tumor Giant Cell Tumor of Tendon Sheath Giant Cell Tumors Joint Diseases Muscular Diseases Musculoskeletal Diseases Neoplasms Neoplasms by Histologic Type Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Synovitis Tendinopathy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Synexus Clinical Research, US INC

Wilmington, North Carolina, 28401, United States

Location status: Recruiting

Location contact

CONTACT

888-581-9246

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of TGCT according to medical records
Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
Has provided informed consent and medical records release

Exclusion criteria

Participant is active in an interventional clinical trial of vimseltinib

Treatment and study plan

Primary outcomes

Duration of Vimseltinib Treatment

Time frame: Baseline up to 12 months
Time to Discontinuation of Vimseltinib

Time frame: Baseline to Discontinuation (Estimated up to 12 months)

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Team

CONTACT

[email protected]

888-724-3274

Sponsors and collaborators

Lead sponsor

Deciphera Pharmaceuticals, LLC

Industry

Registry information

Official study title

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor (MOVE)

Acronym: MOVE

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Jul 20, 2025
Registry last updated: Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting